Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy

The co-administration of hydroxychloroquine with azithromycin is proposed in COVID-19 therapy. We hypothesize a new mechanism supporting the synergistic interaction between these drugs. Azithromycin is a substrate of ABCB1 (P-glycoprotein) which is localized in endosomes and lysosomes with a polariz...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The AAPS journal 2020-06, Vol.22 (4), p.86, Article 86
1. Verfasser:	Scherrmann, JM
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Infective Agents - pharmacology Anti-Infective Agents - therapeutic use ATP Binding Cassette Transporter, Subfamily B - agonists Azithromycin - pharmacology Azithromycin - therapeutic use Biochemistry Biomedical and Life Sciences Biomedicine Biotechnology Commentary Coronavirus Infections - drug therapy COVID-19 Drug Synergism Drug Therapy, Combination Humans Hydroxychloroquine - pharmacology Hydroxychloroquine - therapeutic use Pandemics Pharmacology/Toxicology Pharmacy Pneumonia, Viral - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!